Business Wire

MAVENIR/MOBILEDGEX

22.6.2021 15:02:08 CEST | Business Wire | Press release

Share
Mavenir and MobiledgeX Enable Global Edge Connectivity With Deutsche Telekom

Mavenir, in collaboration with MobiledgeX and Deutsche Telekom, have demonstrated and validated the reference design for deploying cloud-native 5G User Plane Function (UPF) to support Multi-Access Edge Computing (MEC) applications, tailored to each use case need for proximity and performance. The reference design is fully cloud-native, abstracted away from underlying cloud architecture, infrastructure vendor and operating owner.

“We are excited to partner with Mavenir and MobiledgeX to demonstrate dynamic cloud-native deployment of 5G Core UPF for users where it is needed. The UPF can run inside the operator’s owned network, inside a private 4G/5G network, inside the roaming network, or in the public cloud. The ability to dynamically and seamlessly orchestrate traffic across our own footprint and the footprint of others opens up the possibility for new connectivity solutions for customers,” says Alex Choi, SVP Strategy & Technology Innovation, Deutsche Telekom.

A service-based, cloud-native UPF is at the core of the reference design. Since the introduction of mobile packet data in 3G, all data traffic, irrespective of source, destination, and requesting application, has been tunneled back to a limited number of fixed (packet gateway) anchor points inside the mobile networks. This is increasingly inefficient, non-performant, and prone to bottlenecks. 5G Core standards enable dynamic placement of the anchor point (the UPF) based on the application and network’s needs. The combination of Mavenir’s widely deployed 4G/5G cloud-native Converged Packet Core solution, coupled with the MobiledgeX Edge-Cloud platform enables the UPF to be placed on different clouds from different vendors with different ownership. Service provider control, security, and privacy are maintained by a customer’s owning operator at all times, even when roaming. This architecture helps optimal placement of the application’s backend servers, enabling a superior user experience and increased network efficiency, by significantly reducing the distance the data needs to travel before it is processed.

Validated Reference Design

For this trial validation, the Mavenir 5G Core is running in Deutsche Telekom’s network. Two network and vendor-independent cloudlets, located in Germany, have been deployed as valid UPF placements in the 5G Core routing. For instance, a video application is started on a 5G phone connected to Deutsche Telekom’s 5G network in Berlin. The request is sent to the 5G Core that selects UPF placement in the Berlin cloudlet. Tunneling is established. The video request is passed to the local edge-placed video cache and delivery commences. The identical request is made in Hanover. The traffic is then established to the Hanover cloudlet and local fulfillment occurs there. The MobiledgeX Edge Cloud 3.0 platform dynamically controls the secure placement, lifecycle management, and video traffic routing of the edge-based UPF and the video application.

“This is a successful milestone for cloud-native 5G Core traffic routing, giving Deutsche Telekom the freedom to deliver a point of interconnect/local breakouts anywhere in the world, on any cloud,” says Bejoy Pankajakshan, Chief Strategy Officer, Mavenir. “Cloud-native design of 5G network functions integrated with orchestration tools makes it possible to achieve a new level of flexibility in network function placement. Automation, agility, and flexibility are at the heart of this project.”

“The MobiledgeX Edge-Cloud platform enables our operator customers to dynamically manage and allocate UPF functionality across their own cloud infrastructure independent of vendor, in roaming partners mobile networks, in private 4G/5G networks, and in public clouds, all through one pane of glass and in one trusted and secure operation,” says Sunay Tripathi, Chief Technology Officer & EVP of Engineering & Product, MobiledgeX. “Cloud-native UPF operation transforms traffic patterns in mobile operator networks, making the telecom operator the largest customer of their own edge cloud offering which is necessary to be a true cloud leader. We are very excited that Deutsche Telekom has taken the initiative to lead.”

About Mavenir:

Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com

About MobiledgeX

MobiledgeX is working with global mobile operators to deliver full control over multi-cloud edge deployments. The company’s MobiledgeX Edge-Cloud platform provides a common interface for managing application workloads anywhere, abstracted from underlying infrastructure, to maintain control over data, privacy and security. It also provides device native SDK and matching engines for operator and third-party application developers to maximize performance and efficiency for cloud-native applications at the edge. MobiledgeX Edge-Cloud is proven in market today via trials, proofs of concepts and deployments that involve more than 20 global operators and a range of next-gen app developers.

MobiledgeX is an edge computing company founded by Deutsche Telekom AG and headquartered in San Jose, California. https://mobiledgex.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye